Does Entresto Improve Heart Failure Survival Rates?
Entresto (sacubitril/valsartan) significantly reduces mortality in patients with chronic heart failure with reduced ejection fraction (HFrEF). The pivotal PARADIGM-HF trial, involving over 8,400 patients, showed a 20% relative risk reduction in cardiovascular death or heart failure hospitalization compared to enalapril (HR 0.80; 95% CI 0.73-0.87; p<0.001).[1][2] All-cause mortality dropped by 16% (HR 0.84; 95% CI 0.76-0.93; p=0.0009).[1]
How Did the PARADIGM-HF Trial Work?
Patients with HFrEF (ejection fraction ≤40%, later amended to ≤35%) on standard therapy were randomized to Entresto or enalapril. Entresto combines a neprilysin inhibitor with an ARB, enhancing natriuretic peptides while blocking harmful neurohormonal activation. Median follow-up was 27 months, with consistent benefits across subgroups like age, sex, and ejection fraction severity.[1][3]
What Do Real-World Studies Show?
Observational data from registries like CHAMP-HF and ARRA confirm trial results, with lower mortality and hospitalization rates in Entresto users versus ACE inhibitors or ARBs. A 2022 meta-analysis of over 20,000 patients reported a 17% all-cause mortality reduction (HR 0.83; 95% CI 0.75-0.92).[4] Benefits persist in elderly patients and those with comorbidities like diabetes.[5]
Does It Help Heart Failure with Preserved Ejection Fraction (HFpEF)?
PARAGON-HF trial in HFpEF (ejection fraction ≥45%) showed no significant mortality benefit (HR 0.87; 95% CI 0.75-1.01; p=0.059), though hospitalizations decreased by 13%.[6] Entresto is FDA-approved mainly for HFrEF, with HFpEF use off-label or under investigation.
What Side Effects Impact Survival Benefits?
Common issues include hypotension (14% vs 9.2% on enalapril), hyperkalemia, and angioedema (0.3% risk, higher if switching from ACE inhibitors).[1] Discontinuation rates were similar (10.7% vs 12.3%). No excess cancer or renal failure signals emerged long-term.[7]
How Does Entresto Compare to Other HFrEF Treatments?
| Treatment | Mortality Reduction vs Placebo (Key Trial) | Notes |
|-----------|--------------------------------------------|-------|
| Entresto | 20% CV death/HF hosp (PARADIGM-HF)[1] | Superior to enalapril |
| Enalapril | 16% all-cause (SOLVD)[8] | Standard ACE inhibitor |
| Carvedilol | 35% all-cause (COPERNICUS)[9] | Beta-blocker; additive with Entresto |
| SGLT2 inhibitors (e.g., dapagliflozin) | 17% CV death/HF hosp (DAPA-HF)[10] | Now guideline-recommended alongside Entresto |
Guidelines (ACC/AHA 2022) rank Entresto as Class I for HFrEF to reduce mortality.[11]
Sources
[1]: NEJM - PARADIGM-HF
[2]: McMurray et al., Eur Heart J (2014)
[3]: PARADIGM-HF subgroup analyses, Lancet (2016)
[4]: Meta-analysis, Eur J Heart Fail (2022)
[5]: CHAMP-HF registry, JACC (2021)
[6]: NEJM - PARAGON-HF
[7]: FDA label, Novartis
[8]: SOLVD trial, NEJM (1991)
[9]: COPERNICUS, Lancet (2001)
[10]: DAPA-HF, NEJM (2019)
[11]: ACC/AHA HF Guidelines (2022)